文献速递浆细胞疾病

通过扩展遗传谱优化来那度胺维持治疗的价值:Myeloma XI 试验中 556 例患者的分析

Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial.
PubMed 文献 · Blood · 2023-01-01

在 Myeloma XI 试验中,556 例自体干细胞移植后随机接受来那度胺维持或观察的患者接受了扩展分子谱检测。单打击骨髓瘤(尤其孤立 del(1p)、del(17p)、t(4;14))从维持治疗中获益最大,而孤立 gain(1q) 无获益,双打击骨髓瘤获益有限。

要点

  • 单打击骨髓瘤从来那度胺维持治疗中获得的 PFS 获益最高,孤立 del(1p) 风险降低约 40 倍。
  • 孤立 gain(1q) 患者从来那度胺维持治疗中未获益。
  • 双打击骨髓瘤(≥2 个风险标志)患者从来那度胺维持治疗中获益有限。

核心结论

  • 扩展遗传谱可识别从来那度胺维持治疗中获得异常获益的患者,应考虑用于新诊断患者以支持治疗路径中的管理讨论。

研究设计与样本

  • 研究纳入 National Cancer Research Institute Myeloma XI 试验中自体干细胞移植后随机接受来那度胺维持或观察的患者,共 556 例,检测 t(4;14)、t(14;16)、t(14;20)、del(1p)、gain(1q)、del(17p) 并计算风险标志共现。
  • 从维持随机化起计算无进展生存期(PFS)、后续进展(PFS2)和总生存期(OS),组间比较采用 Cox 比例风险回归。

主要发现

  • 556 例患者中,双打击骨髓瘤(≥2 个风险标志)占 17%,单打击(1 个风险标志)占 32%,无风险标志占 51%。
  • 单打击骨髓瘤从来那度胺维持治疗中获得最高 PFS 获益,孤立 del(1p)、del(17p)、t(4;14) 分别较观察组降低进展或死亡风险约 40 倍、10 倍和 7 倍。
  • 该获益转化为单打击组较观察组改善的 PFS2 和 OS;观察组 vs 来那度胺维持组的中位 PFS 为 10.9 vs 57.3 个月。
  • 孤立 gain(1q) 患者未获益,双打击骨髓瘤(无论涉及何种风险病变)从来那度胺维持治疗中获益有限。

临床怎么用

  • 作者认为,扩展遗传谱可识别从来那度胺维持治疗中获得异常获益的患者,应考虑用于新诊断患者以支持治疗路径中的管理讨论。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prediction of individual patient benefit from lenalidomide (Len) maintenance after autologous stem cell transplant (ASCT) remains challenging. Here, we investigated extended molecular profiling for outcome prediction in patients in the National Cancer Research Institute Myeloma XI (MyXI) trial. Patients in the MyXI trial randomized to Len maintenance or observation after ASCT were genetically profiled for t(4;14), t(14;16), t(14;20), del(1p), gain(1q), and del(17p) and co-occurrence of risk markers was computed. Progression-free survival (PFS), subsequent progression (PFS2), and overall survival (OS) were calculated from maintenance randomization, and groups were compared using Cox proportional hazards regression. Of 556 patients, 17% with double-hit multiple myeloma (MM) (≥2 risk markers), 32% with single-hit (1 risk marker), and 51% without risk markers were analyzed. Single-hit MM derived the highest PFS benefit from Len maintenance, specifically, isolated del(1p), del(17p), and t(4;14), with ∼40-fold, 10-fold, and sevenfold reduced risk of progression or death (PFS), respectively, compared with observation. This benefit translated into improved PFS2 and OS for this group of patients compared with observation; median PFS was 10.9 vs 57.3 months for observation vs Len maintenance. Patients with isolated gain(1q) derived no benefit, and double-hit MM limited benefit (regardless or risk lesions involved) from Len maintenance. Extended genetic profiling identifies patients deriving exceptional benefit from Len maintenance and should be considered for newly diagnosed patients to support management discussions along their treatment pathway. This trial was registered at www.isrctn.com/ISRCTN49407852 as # ISRCTN49407852.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Panopoulou A, Cairns DA, Holroyd A, et al. Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial. Blood. 2023. PMID: 36564045. doi:10.1182/blood.2022018339

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。